Terns Pharmaceuticals has appointed Erin Quirk to serve as its chief medical officer. Quirk most recently worked at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where she was vice president, clinical research. Terns, which has operations in San Mateo, CA, and Shanghai, China, raised $30 million in financing last year to support development of drugs for the fatty liver disease nonalcoholic steatohepatitis.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
